Medicure (CVE:MPH) Hits New 52-Week High – Time to Buy?

Medicure Inc. (CVE:MPH) reached a new 52-week high during trading on Friday. The company traded as high as C$4.40 and last traded at C$4.43, with a volume of 15,100 shares traded. The stock had previously closed at C$4.40.

Medicure Stock Performance

The company has a debt-to-equity ratio of 6.02, a current ratio of 0.97 and a quick ratio of 1.28. The stock’s 50-day moving average price is C$2.95 and its 200 day moving average price is C$1.60. The firm has a market cap of C$44.87 million, a P/E ratio of -5.97 and a beta of 0.98.

Medicure Company Profile

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.